Navigation Links
New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
Date:9/25/2008

- Transdermal Estrogen Analyses Continue to Show Benefits of Hormone

Therapy Use in Menopausal Women -

MAPLE GROVE, Minn., Sept. 25 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. today announced that clinical abstracts featuring Divigel(R) (estradiol gel) 0.1% were presented at the North American Menopause Society's 19th Annual Meeting in Orlando, Florida. Divigel(R) is a transdermal estrogen therapy that was approved by the FDA in June 2007. It offers the lowest approved dose of estradiol gel for the treatment of moderate to severe hot flashes associated with menopause.

"These analyses indicate that Divigel(R) (estradiol gel) 0.1% is a valuable alternative for certain postmenopausal women with moderate to severe hot flashes," said Ronald Ackerman, MD, FACOG, CEO and principal investigator, Comprehensive Clinical Trials. "Analyses like these are crucial to further educate women about the benefits of hormone therapy for the management of hot flashes."

The first abstract presented at the meeting was a post-hoc analysis of 488 patients from a Phase III clinical trial to determine the effect of uterine status (intact, absent) plus Divigel(R) (1.0 g/day, 0.5 g/day, 0.25 g/day) compared to placebo on the change from baseline to week 12 in the frequency and severity of hot flashes. This study revealed that Divigel(R) is an effective treatment for the relief of moderate to severe hot flashes in postmenopausal women regardless of ovarian or uterine status.

The second abstract used the same patient population to evaluate the effect of age (<50 years, 50-59 years, greater than or equal to 60 years) and age plus Divigel(R) (1.0 g/day, 0.5 g/day, 0.25 g/day) combined compared to placebo on the change from baseline to week 12 in frequency and severity of moderate to severe hot flashes. This study revealed that Divigel(R) is an effective treatment for relief of hot flashes in postmenopausal women of any age; however, the e
'/>"/>

SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
10. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
11. AGI Dermatics Clinical Data Indicate Bicyclic Monoterpene Diols Suppress MMP1 and Stimulate Collagen Through TNF-a Signaling

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)..., IRVINE,Calif.,Nov.23/PRNewswire/--AdvancedSte...ventionsolutionprovider,announcedtodaytheacquisiti...,aprivatelyhelddeveloperofinnovativedisinfectionpr...infections.Termsoftheacquisitionwerenotdisclosed. ...eadecontaminationtechnologythatprovidesdisinfectio...
(Date:11/20/2009)... , BOSTON, Nov. 20 The Uni... upheld an earlier District Court ruling yesterday...ge Wholesale Price (AWP) pharmaceutical litigation... (Logo: http://www.newscom.com/cgi-bin/prnh/20080...ment that awarded consumers who purchased the phar...
(Date:11/20/2009)... , LOUISVILLE, Ky., Nov. 20 /PRNewswire/ -...tigators (NADDI) today announced a new initiative ...rsor Log Exchange (NPLEx) is a multi-state electro...tions on over-the-counter (OTC) medicines containi...le. The technology for NPLEx is based on a system...
Breaking Medicine Technology:ASP Announces Acquisition of Gloster Europe to Help Reduce Infections in Healthcare Facilities 2U.S. Court of Appeals Upholds AstraZeneca AWP Settlement 2U.S. Court of Appeals Upholds AstraZeneca AWP Settlement 3National System Aims To Minimize Diversion of Cold and Allergy Medicine in Methamphetamine Production 2National System Aims To Minimize Diversion of Cold and Allergy Medicine in Methamphetamine Production 3KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 1KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 2KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 3KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 4Scientists remove amyloid plaques from brains of live animals with Alzheimers disease 10367 1Scientists remove amyloid plaques from brains of live animals with Alzheimers disease 10367 2SAMHSA Honors The Soloist Greys Anatomy United States Of Tara and Mental Health Consumer Leaders at The Star Studded 2009 Voice Awards 59512 1SAMHSA Honors The Soloist Greys Anatomy United States Of Tara and Mental Health Consumer Leaders at The Star Studded 2009 Voice Awards 59512 2SAMHSA Honors The Soloist Greys Anatomy United States Of Tara and Mental Health Consumer Leaders at The Star Studded 2009 Voice Awards 59512 3SAMHSA Honors The Soloist Greys Anatomy United States Of Tara and Mental Health Consumer Leaders at The Star Studded 2009 Voice Awards 59512 4
...esented on Valopicitabine Combined,with an Investi...il 12, 2007 /PRNewswire-FirstCall/ --,Idenix Pharm...phase,IIb studies of the novel combination of valo...a (Pegasys(R)) in both treatment-naive,and treatme...e-1,strain of the hepatitis C virus (HCV). These d...
...osts of eradicating,poliomyelitis from the remaini...m, are much lower than the long term costs of tryi...a recently developed,monovalent vaccine is almost ...litis than an existing trivalent vaccine. These ar...d in an upcoming,issue of The Lancet. , Both Artic...
Other Medicine Technology:Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 2Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 3Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 4Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 5Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 6Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 7Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 2Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 3
(Date:11/23/2009)...explain why more blacks die than whites, study fin...-- Body weight and co-existing health problems don...wer survival rates than whites, U.S. researchers s... lower survival rates than whites for nearly all c...e explored a variety factors, such as differences ...
(Date:11/23/2009)....,Nov.23/PRNewswire/--HealthLeaders-InterStudy,ale...tsthatself-insuredmembercompaniesthatarepartofMilw...regatehealthcare-costdecreaseof1.5percentperhealth...gh-performanceprovidernetwork.Accordingtothe Milwa...uredmembercompaniessaved$44millioninhealthcarecost...
(Date:11/23/2009)...PRNewswire-FirstCall/--NewCardio,Inc.,(OTCBulletin...nouncedtodaythatCEO,Dr.BranislavVajdic,andCFO,Rich...erenceonThursday,December3rd,at4:30PMPSTattheLuxeS...lbeavailableforone-on-onemeetingsonWednesday,Decem...meeMaasat(646)536-7331or brett@haydenir.com torequ...
(Date:11/23/2009)...swire-FirstCall/--ArcadiaResources,Inc.(NYSEAmex: ...reservicesundertheArcadiaHealthCare(SM)()brand,ann...dsaleofsharesofitscommonstockandwarrantstopurchase...stitutionalinvestors,representinggrossproceedstoAr...rmsofseparateSubscriptionAgreementswiththeinvestor...
(Date:11/23/2009)...tion about Oxycodone use is now just a click away ...site is a statistical database that reports the s...ounty in the United States. The data is compiled b...eational or medicinal use. , ...egal and illegal Oxycodone statistics and inform...
Breaking Medicine News(10 mins):Health News:Weight May Not Drive Racial Disparities in Colon Cancer 2Health News:Milwaukee Employers See Cost Savings with High-Performance Provider Network 2Health News:NewCardio, Inc. to Present at 2nd Annual LD MICRO Conference 2Health News:NewCardio, Inc. to Present at 2nd Annual LD MICRO Conference 3Health News:Arcadia Resources Announces Closing of $11.1 Million Financing 2Health News:DopeStats.com Provides Statistics on Oxycodone Abused in Non-Medical Purposes 2
...nsible for nearly half (49 per cent) of all deaths...e each year. Reducing cholesterol is one of the mo... Both soy protein and plant sterols extracted fr... on cholesterol-lowering however recently the US s...
...omen to tobacco smoke causes genetic damage// in t... studies have shown that smoking during pregnancy ... can be detected at birth. Stephen G. Grant, ...from the earlier study and shows that passive - or...
...hildren getting affected by illnesses due to expos...from the figures of 1998 to 2002, reports a resear...pesticides in the school environment is a health r...erty, with some schools at risk of pesticide expos...
...Indian Medical Association (IMA) has today warned ...areful while treating or dealing with patients who...result of some of the Maoist violence taking place...sed anger and panic among doctors in North Bihar S...
...e stem cell therapy can be used successfully to tr...s University School of Medicine had showed that it... such a way. In just two months, stem cells... percent to 75 percent. The findings are t...
... of India is planning to incorporate penal provisi...ll 2005 to make licensed drug manufacturers who ar...cts in such a look-alike manner a criminal act. Of...uld be mistaken for the other drug under the defin...
Other Medicine News:Health News:Exposure to Pesticides in Schools Produces Illnesses Among Employees, Students 2Health News:Stem Cell Therapy For Treating Heart Attacks 2Health News:Clampdown On Fake Drugs Manufacturers In India – New Bill Enacte 2
FF 450plus IR
... for fast and easy operation with advanced lens me...utomatically held when the lens is properly aligne...The sophisticated alignment system guides you to c...designed with a small footprint, occupying little ...
CR6-45NM Non-Mydriatic Retinal Camera
TRC-50FXC
Medicine Products: